5-Amino-1MQ 50mg/capsule, 60 caps
5-Amino-1MQ 50mg/capsule, 60 caps
Currently unavailable
NovaMeds
Ramelteon is a synthetic melatonin analogue studied for selective agonist activity at melatonin receptor subtypes MT1 and MT2 in experimental models.
Presentation: Ramelteon 8mg/capsule, 60 caps.
Illustrative packaging generated with AI.
Not for human or veterinary use.
Ramelteon is a synthetic melatonin analogue studied for selective agonist activity at melatonin receptor subtypes MT1 and MT2 in experimental models.
The compound’s indanyl-furan scaffold structure confers high binding affinity at MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), with research interest in its proposed role in circadian rhythm entrainment and sleep-wake cycle regulation pathway research.
Ramelteon is distinguished from other sleep-pathway research compounds by the absence of activity at GABA receptors, making it a selective research tool for isolating melatonergic pathway contributions in circadian signalling studies. Research applications include MT1/MT2 receptor pharmacology, circadian rhythm pathway studies, and comparative melatonin analogue receptor binding research.
| Chemical Formula | C16H21NO2 |
|---|---|
| Synonyms | TAK-375, Rozerem, (S)-N-[2-(2,6,7,8-Tetrahydro-1H-indeno[5,4-b]furan-8-yl)ethyl]propionamide |
| Molar Mass | 259.34 g/mol |
| CAS Number | 196597-26-9 |
| Pubchem CID | 208902 |
| Total Compound Content | 480mg (8mg per capsule) |
| Shelf Life | 36 months |
Ramelteon is a synthetic melatonin receptor agonist studied for high-affinity, selective binding at MT1 and MT2 receptor subtypes expressed in the suprachiasmatic nucleus (SCN) in laboratory research models. The compound’s indanyl-furan structural scaffold is studied for its contribution to receptor binding selectivity, with research demonstrating substantially greater affinity at MT1 and MT2 relative to the MT3 receptor subtype and no measurable binding at a broad panel of other receptor binding sites including benzodiazepine, dopamine, and opiate receptors. Research models have examined Ramelteon’s proposed downstream effects on circadian rhythm entrainment pathway signalling, including modulation of SCN neuronal firing rhythm patterns and phase-shifting properties in rodent circadian models. Comparative receptor pharmacology research has examined Ramelteon alongside other melatonin analogues and native melatonin to characterise structure-activity relationships governing MT1/MT2 selectivity. Independently third-party HPLC-tested; COA available per batch.
Ramelteon demonstrates high binding affinity at MT1 and MT2 receptor subtypes with substantially lower affinity at MT3, and no measurable binding at a broad panel of other receptor binding sites including benzodiazepine, dopamine, opiate, and ion channel targets. This selectivity profile makes Ramelteon a standard tool compound in research examining specifically melatonergic receptor contributions to circadian rhythm and sleep-wake cycle pathway signalling, without the confounding receptor activities associated with non-selective melatonin ligands.
Rodent circadian models measuring wheel-running activity rhythms and SCN neuronal firing patterns are standard experimental systems for studying Ramelteon’s proposed phase-shifting and entrainment properties, typically examining the magnitude and direction of circadian phase shifts induced by compound administration at different circadian time points relative to vehicle controls. Ex vivo SCN electrophysiology preparations complement these in vivo approaches by allowing direct measurement of neuronal firing rate modulation following compound exposure.
Ramelteon’s indanyl-furan scaffold is structurally distinct from native melatonin’s indole-based structure, a difference studied in comparative structure-activity relationship research examining how the two structural frameworks interact with MT1/MT2 receptor binding sites. Ramelteon’s scaffold confers significantly higher binding affinity at MT1 and MT2 relative to native melatonin, making it a useful reference compound for distinguishing high-affinity versus low-affinity melatonin receptor binding contributions in circadian research models.
Capsule excipients are not specified in the available product documentation.